Search

Displaying results 7551 - 7560 of 10000 in total
  1. Drug

    Lepzacitinib

    go.drugbank.com/drugs/DB21646
    Investigational

    Lepzacitinib has a monoisotopic molecular weight of 355.16 Da. … The usage of the INN stem '-citinib' in the name indicates that Lepzacitinib is a Janus kinase inhibitor.

  2. Drug

    Pebezertinib

    go.drugbank.com/drugs/DB21705
    Investigational

    Pebezertinib has a monoisotopic molecular weight of 497.16 Da. … The usage of the INN stem '-ertinib' in the name indicates that Pebezertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  3. Drug

    Inlexisertib

    go.drugbank.com/drugs/DB21713
    Investigational

    Inlexisertib has a monoisotopic molecular weight of 535.29 Da. … The usage of the INN stem '-sertib' in the name indicates that Inlexisertib is a serine/threonine kinase inhibitor.

  4. Drug

    TST10088

    go.drugbank.com/drugs/DB05151
    Experimental

    TST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating proteins. … Cleavage of the peptide switch activates the prodrug causing ribosomal inactivation and the death of cancerous cells.

  5. Drug

    Mesmulogene ancovacivec

    go.drugbank.com/drugs/DB06584
    Investigational

    Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens … Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. [L5191]

  6. Drug

    Ad5-nCoV

    go.drugbank.com/drugs/DB15655
    Investigational

    [L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906 … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination

  7. Drug

    SB 11285

    go.drugbank.com/drugs/DB17511
    Investigational

    SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. … [L45123] SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors).

  8. Drug

    BBM-H803

    go.drugbank.com/drugs/DB17700
    Investigational

    It consists of an adeno-associated virus vector containing an expression cassette of the human Factor VIII transgene.

  9. Drug

    SIG-007

    go.drugbank.com/drugs/DB17710
    Experimental

    Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153] … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.

  10. Drug

    Alethine

    go.drugbank.com/drugs/DB05800
    Investigational

    Alethine is studied in the treatment of cancer. It belongs to a family of chemicals called disulfides.